Liver
Liver cirrhosis
The end result of chronic liver injury: fibrous septa link the portal tracts and surround regenerative nodules of liver cells, destroying the normal architecture and blood flow. It causes portal hypertension and, as liver cells are lost, liver failure.
Causes et facteurs de risque
- Alcohol
- Chronic viral hepatitis B or C
- Non-alcoholic fatty liver disease
- Biliary disease, including long-standing obstruction (biliary cirrhosis) and primary biliary cirrhosis
- Inherited: haemochromatosis, Wilson’s disease, α1-antitrypsin deficiency
- No cause found: cryptogenic cirrhosis
Aspect macroscopique
- The capsule is markedly bumpy, and the liver tends to shrink as the disease advances.
- Micronodular cirrhosis: nodules of 3 mm or less, often yellow-brown from coexisting fatty change; typical of alcohol.
- Macronodular cirrhosis: nodules larger than 3 mm with broad tan scars; typical of viral hepatitis. Most causes can give either pattern, so the pattern does not reveal the cause.
- In liver failure, some nodules turn green-tinged from retained bile after fixation.
Au microscope
- Thick bands of collagen (fibrous septa) ring nodules of regenerating liver cells; the normal plates running from portal tracts to central veins are lost.
- Lymphocytes and proliferating bile ductules lie within the fibrous bands.
- The normal fine reticulin network (type IV collagen) is replaced by heavy type I and III collagen.
Évolution
- Persistent or repeated injury kills liver cells; Kupffer cells and liver cells release cytokines such as PDGF and TNF.
- Stellate cells in the space of Disse are activated and turn into myofibroblast-like cells that make collagen.
- Fibrous bands bridge portal tracts and hepatic veins; surviving liver cells regenerate as nodules.
- Over at least a decade: Fibrosis and nodules distort the vessels, creating portosystemic shunts: portal pressure rises.
- With continued loss of liver cells, liver function fails (decompensation).
Complications
- Portal hypertension: splenomegaly, oesophageal varices (which can bleed), caput medusae, haemorrhoids
- Ascites, from sinusoidal hypertension, low albumin and sodium and water retention (secondary hyperaldosteronism)
- Hepatic encephalopathy, from toxins such as ammonia that the liver no longer clears
- Hepatorenal syndrome
- Hepatocellular carcinoma, from the increased cell turnover in regenerating nodules
Examens complémentaires
- Liver function tests
- Low albumin and a prolonged prothrombin time (failing synthesis) and raised bilirubin; transaminases may be only mildly raised.
- Ultrasound and elastography
- A small, nodular liver, an enlarged spleen and ascites; elastography measures the stiffness of the fibrotic liver.
- Liver biopsy
- Confirms fibrous septa surrounding regenerative nodules and may show the cause.
- Tests for the cause
- Hepatitis B and C serology, iron studies (haemochromatosis), autoantibodies and caeruloplasmin (Wilson disease).
- Upper endoscopy
- Oesophageal varices from portal hypertension.
Traitement médicamenteux
- β-Adrenergic blockers (β-blockers): Drugs that block β receptors, slowing the heart and reducing its work and oxygen use; used in angina, after myocardial infarction, in hypertension and in heart failure.
- Lactulose (osmotic laxative): A non-absorbable sugar that acidifies the colon, trapping ammonia: the main treatment for hepatic encephalopathy in cirrhosis, and an osmotic laxative.
- Aldosterone antagonists: Potassium-sparing diuretics that block the aldosterone receptor in the collecting tubule; spironolactone is the diuretic of choice for ascites in cirrhosis.
- Loop diuretics: The most powerful diuretics: they block salt reabsorption in the loop of Henle, relieving fluid overload in heart failure, ascites and pulmonary oedema.
- Somatostatin analogues: Long-acting versions of somatostatin that suppress growth hormone, gut hormones and splanchnic blood flow: used in acromegaly from pituitary adenomas, neuroendocrine tumours and bleeding oesophageal varices.
Médicaments à éviter ou à utiliser avec précaution
- Statins (HMG-CoA reductase inhibitors) (Avec précaution): Statins are cleared by the liver and can raise transaminases; they are contraindicated in active or decompensated liver disease.
- Oral anticoagulants (warfarin and the direct oral anticoagulants) (Avec précaution): The liver already makes fewer clotting factors and clears these drugs less well: bleeding risk rises.
- Leukotriene receptor antagonists (Avec précaution): Zileuton can damage the liver.
- Thiopurines (azathioprine, mercaptopurine) (Avec précaution): They can damage the liver.
- Loop diuretics (Avec précaution): Rapid fluid and potassium loss can precipitate hepatic encephalopathy and kidney failure; they are combined with spironolactone.
- Vasopressin V2 receptor antagonists (tolvaptan) (Contre-indiqué): Tolvaptan can cause serious liver injury.
- Non-steroidal anti-inflammatory drugs (NSAIDs) (Avec précaution): They can precipitate kidney failure and bleeding in cirrhosis with ascites.
- Paracetamol (acetaminophen) (Avec précaution): Glutathione stores are low and enzymes that make NAPQI are induced: liver damage occurs at lower doses.
- Opioid analgesics (Avec précaution): They are cleared by the liver and can precipitate hepatic encephalopathy.
- Macrolides (Avec précaution): They are metabolised by the liver and can cause hepatitis.
- Nitroimidazoles (metronidazole) (Avec précaution): It is metabolised by the liver and accumulates.
- Antituberculosis drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) (Avec précaution): Three of the four first-line drugs can damage the liver; the risk is higher and regimens may be changed.
- Antithyroid drugs (thionamides) (Avec précaution): It can cause fulminant liver failure.
- Alkylating agents (cyclophosphamide, temozolomide, dacarbazine) (Avec précaution): Both are activated by the liver.
- Microtubule inhibitors (vinca alkaloids and taxanes) (Avec précaution): They are cleared by the liver (CYP3A4).
- Methotrexate (antifolate) (Contre-indiqué): It causes fibrosis and cirrhosis, more so in a damaged liver.
- EGFR tyrosine kinase inhibitors (Avec précaution): They are cleared by the liver.
Anatomie concernée
Sujets liés
Rédigé d’après
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 8, The Liver and Biliary Tract, pp. 228–230, figs 8-13 to 8-20
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.